Today: 18 July 2026
Browse Category

Biotechnology 16 June 2026 - 18 July 2026

AtaiBeckley Inc. (NASDAQ:ATAI) stock jumps as FDA staffing guidance spotlights BPL-003’s two-hour edge

AtaiBeckley Inc. (NASDAQ:ATAI) stock jumps as FDA staffing guidance spotlights BPL-003’s two-hour edge

AtaiBeckley Inc. shares climbed 15.6% to about $5.75 in Tuesday afternoon trading as investors weighed final U.S. Food and Drug Administration guidance for psychedelic-drug trials. The document expects two monitors to remain with a patient throughout a treatment session, making BPL-003’s roughly two-hour clinic model more relevant to operating costs. Duration is now a cost variable.
14 July 2026
··
NextCure stock surge puts cash payout and 1.21% Avere stake under the lens

NextCure stock surge puts cash payout and 1.21% Avere stake under the lens

NextCure, Inc. shares nearly tripled on Tuesday after the cancer-drug developer agreed to merge with privately held Avere Therapeutics and pair the transaction with a $320 million financing. Yet current holders are expected to own just 1.21% of the combined company, making the rally a wager on a possible cash distribution, a contingent-value right and a higher public valuation for Avere—not merely the financing headline.
14 July 2026
··
Virax Biolabs (NASDAQ:VRAX) Soars 183% After Fosun Deal

Virax Biolabs (NASDAQ:VRAX) Soars 183% After Fosun Deal

Virax Biolabs Group shares jumped more than 100% during Thursday’s U.S. session after the diagnostics company said its UK subsidiary reached an exclusive multi-country supply deal with Fosun Diagnostics for its ImmuneSelect research-use immune-profiling line. The Nasdaq stock was trading at $9.00 as of 11:52 a.m. EDT, up $5.82 on the day, with about 57.8 million shares changing hands.
9 July 2026
··
Abivax (NASDAQ:ABVX) ADS gain $2.3B after obefazimod safety news; Paris session yet to start

Abivax (NASDAQ:ABVX) ADS gain $2.3B after obefazimod safety news; Paris session yet to start

Abivax S.A. is set for a lagged Paris opening after its U.S. ADS jumped in after-hours trading. Investors reacted to new clinical data on obefazimod, Abivax’s ulcerative colitis drug. The latest news hits late, but the drop earlier this month wasn’t about whether the drug works. It was about the potential cancer risk and what that could mean for the drug’s label.
30 June 2026
···
AbbVie moves to acquire Apogee in $10.9 billion bet on immunology

AbbVie moves to acquire Apogee in $10.9 billion bet on immunology

AbbVie said Monday it’s buying Apogee Therapeutics for $10.9 billion in cash, making this its largest deal since 2019. The company is looking to strengthen its immunology pipeline with Apogee’s long-acting immune-disease drugs. AbbVie and Apogee put out a joint release on the agreement, according to a securities filing. They expect the deal to close in the third quarter of 2026.
22 June 2026
··
uniQure Gets Go-Ahead From FDA for AMT-130 Huntington’s Gene Therapy Application

uniQure Gets Go-Ahead From FDA for AMT-130 Huntington’s Gene Therapy Application

uniQure said Wednesday the U.S. Food and Drug Administration will let it use three-year data from its early Huntington’s gene therapy trial as the basis for an accelerated approval filing, changing course in the dragged-out regulatory battle over the therapy. The company will go ahead with a biologics license application in the third quarter. That application is the standard FDA process for marketing a biologic drug in the U.S.
17 June 2026
·
Regentis Biomaterials Stock Falls Premarket After 506% Surge on Scrapped Share Offering

Regentis Biomaterials Stock Falls Premarket After 506% Surge on Scrapped Share Offering

Regentis Biomaterials Ltd. shares turned lower in early Tuesday trading after a huge Monday rally that was driven by the removal of a near-term share-sale overhang. RGNT closed June 15 at $9.40, up 506.45% on the day, before Google Finance showed the stock indicated at $6.80 in premarket trading, down 27.66%. The same quote page listed an intraday high of $15.50, a low of $1.69 and a market capitalization of about $48.69 million, underscoring how thinly traded small-cap biotech and medtech names can swing sharply when news changes the supply-demand picture for shares.
16 June 2026
··
Intellia Therapeutics Stock Jumps as CRISPR Therapy Data Put FDA Filing in Focus

Intellia Therapeutics Stock Jumps as CRISPR Therapy Data Put FDA Filing in Focus

Intellia Therapeutics shares surged Monday as investors reacted to additional late-stage data for lonvoguran ziclumeran, or lonvo-z, the company’s one-time CRISPR-based therapy for hereditary angioedema, a rare genetic disease that causes unpredictable and potentially life-threatening swelling attacks. The Nasdaq-listed biotech was recently trading at $14.92, up roughly 23%, with volume far above normal levels. Stocks rise when new information increases expected future sales, profits or approval odds; they fall when investors see lower odds, higher risks or dilution.
16 June 2026
··
1 2 3 … 19
Go toTop